Patenting antibodies has long been challenging. Although most inventions can be patented based on their functionality, assuming the functionality is new and non-obvious, for antibodies and other biomolecules there is a higher standard. Although the antibody standard was recently challenged, the U.S. Court of Appeals for the Federal Circuit (CAFC) decided to uphold it.
The
Latest Post
More Posts
Drug Patent Invalid Due to Poor Quality Translation
Patenting COVID-19 Tests: Avoiding the Common Pitfalls
A Method of Diagnostic Sample Preparation Is Held Valid Under Mayo/Myriad, but the Diagnostic Test Was Held Invalid
For the First Time, a Medical Treatment Patent Is Ruled Invalid Under Mayo/Myriad
Detecting Disease Is Not a “Tangible and Useful Result” Eligible for Patenting
Eliminate Medical Treatment Patents? An Effort Approaches the Supreme Court
Patenting Diagnostics and Biomarkers Six Years After Mayo
Rules for Patenting Genetic Biomarkers Are Updated in Roche v. Cepeid
A Rare Win for a Medical Testing Patent in Exergen Corporation V. Kaz USA, Inc.
Subscribe: Subscribe via RSS
Blogs
Firm/Org